The controversial U.S. Food and Drug Administration approval of the Alzheimer disease drug Aduhelm should be investigated by the Office of Inspector General (OIG), FDA Acting Commissioner Janet Woodcock, M.D., has said.
The OIG's Office of the Inspector General (OIG) has lifted the mandate of the Caring Voice Coalition (CVC), one of the largest patient-aid charities in the United States